Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 earnings, revealing underperformance in revenue and ARR compared to expectations. The company's shift towards a cloud-native architecture aimed at maximizing AI scalability led to delays in major U.S. government deals due to foreign entity status administrative hurdles. The Insights digital forensic solution captured 65% of the installed base, but pricing and footprint expansion gains fell short of expectations, particularly in U.S. state and local government sectors.

Management is now focusing on sales execution rigor, executive sponsorship, and forecasting precision. The full-year ARR guidance was revised to $550 million–$560 million, with potential upside removed from large, complex government contracts due to unpredictable sales cycles. Full-year adjusted EBITDA targets were raised to $153 million–$159 million, accounting for headcount management and operational efficiency gains.

Growth expectations for Corellium were moderated, while Guardian, Pathfinder, and Genesis growth targets were lowered. New EU data sovereignty laws and foreign entity permit requirements added to administrative complexities. Genesis, launched as a consumption-based product, showed early promise with $400,000 ARR secured within weeks of its release.